RNA therapeutics are highly dependent on in vivo transfer systems. For this purpose, we investigated the exclusively in-licensed and further developed proprietary LNP (fLNP) technology. In our latest biodistribution study, fLNPs have demonstrated their true potential and biocompatibility.
In-house in vivo analyses, as well as extended mouse studies, conducted by our partner CRO, have confirmed the extraordinary transfer efficiency as well as pre-targeting ability to different organs, depending on formulation and functionalization capacity, of fLNPs.
In these biodistribution studies, fLNPs were superior to commercial in vivo delivery reagents when directly compared. The successful conclusion of these studies, further strengthens the broad applicability of seRNA therapeutics in various indications.